An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit

Trial Profile

An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs BI 894999 (Primary)
  • Indications Diffuse large B cell lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Aug 2018 Planned End Date changed from 15 Nov 2019 to 20 May 2021.
    • 16 Apr 2018 Planned primary completion date changed from 5 Apr 2018 to 19 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top